Abstract LB-223: Intratumoral accumulationentrapment of doxorubicin by tumor vascular infarction with retargeted tissue factor tTF-NGR

Truncated tissue factor (tTF) retargeted to tumor vasculature by C-terminal GNGRAHA peptide (tTF-NGR) is able to induce tumor vessel infarction. Here, we describe the identification of the optimum therapeutic regimen for the use of tTF-NGR (or a random-PEGylated derivative of tTF-NGR) in combination...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 76; no. 14_Supplement; pp. LB - 223-LB-223
Main Authors Stucke-Ring, Janine, Ronnacker, Julian Timo, Brand, Caroline, Mantke, Verena, Hltke, Carsten, Schliemann, Christoph, Kessler, Torsten, Mesters, Rolf M, Schwppe, Christian, Berdel, Wolfgang E
Format Journal Article
LanguageEnglish
Published 15.07.2016
Online AccessGet full text

Cover

More Information
Summary:Truncated tissue factor (tTF) retargeted to tumor vasculature by C-terminal GNGRAHA peptide (tTF-NGR) is able to induce tumor vessel infarction. Here, we describe the identification of the optimum therapeutic regimen for the use of tTF-NGR (or a random-PEGylated derivative of tTF-NGR) in combination with the chemotherapeutic agent doxorubicin in vitro and in vivo.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Feature-2
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.AM2016-LB-223